Home > Research > Publications & Outputs > Response adaptive designs for Phase II trials w...


Text available via DOI:

View graph of relations

Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measures

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Article number107187
<mark>Journal publication date</mark>1/06/2021
<mark>Journal</mark>Computational Statistics and Data Analysis
Number of pages14
Publication StatusPublished
Early online date30/01/21
<mark>Original language</mark>English


In many rare disease Phase II clinical trials, two objectives are of interest to an investigator: maximising the statistical power and maximising the number of patients responding to the treatment. These two objectives are competing, therefore, clinical trial designs offering a balance between them are needed. Recently, it was argued that response-adaptive designs such as families of multi-arm bandit (MAB) methods could provide the means for achieving this balance. Furthermore, response-adaptive designs based on a concept of context-dependent (weighted) information criteria were recently proposed with a focus on Shannon’s differential entropy. The information-theoretic designs based on the weighted Renyi, Tsallis and Fisher informations are also proposed. Due to built-in parameters of these novel designs, the balance between the statistical power and the number of patients that respond to the treatment can be tuned explicitly. The asymptotic properties of these measures are studied in order to construct intuitive criteria for arm selection. A comprehensive simulation study shows that using the exact criteria over asymptotic ones or using information measures with more parameters, namely Renyi and Tsallis entropies, brings no sufficient gain in terms of the power or proportion of patients allocated to superior treatments. The proposed designs based on information-theoretical criteria are compared to several alternative approaches. For example, via tuning of the built-in parameter, one can find designs with power comparable to the fixed equal randomisation’s but a greater number of patients responded in the trials.